Immix Biopharma | Investor Presentation Deck | 62 slides · page 29 of 62
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.
Pitch deck · why_now · argue_timing · overcrowded density
Slide locked Sign in to view
Slide schematic 8/8
chart 1/1 list 2/2 source-note 1/1 table 1/1 title 3/3
Components 8
bar-vertical bullet numbered source-note data headline headline headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1